This is a phase I study to evaluate the safety and tolerability of Sorafenib in combination
with Temodar and radiation therapy in patients with newly diagnosed high grade glioma
(glioblastoma, gliosarcoma, anaplastic astrocytoma and anaplastic oligodendroglioma or
oligoastrocytoma). The mechanism of action of sorafenib, an oral multikinase inhibitor, makes
it an interesting drug to investigate in the treatment of patients with high grade glioma as
this agent has anti-angiogenic activity and inhibits other pathways such as Ras,
Platelet-derived growth factor (PDGF) and fms-like tyrosine kinase receptor-3 (Flt-3), which
are potential targets against gliomas.